A new artificial intelligence based model called SCORPIO has been developed by researchers from Memorial Sloan Kettering Cancer Center and the Tisch Cancer Institute at Mount Sinai to predict whether cancer patients will benefit from immune checkpoint inhibitors, a type of immunotherapy. The model uses routine blood tests and clinical data to make predictions, making it more accessible and cheaper than current methods. According to Dr Luc Morris, a surgeon and research lab director at MSK, the model outperforms currently used tests in predicting outcomes. The study, which included nearly 10,000 patients across 21 different cancer types, was led by Dr Morris and Diego Chowell, an Assistant Professor of Immunology and Immunotherapy at Mount Sinai. The research was supported by the National Institutes of Health and other organizations, and has the potential to make immunotherapy more widely available and effective for cancer patients.
↧